Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Patent
1995-06-07
1998-11-03
Kight, John
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
424 165, 424 111, 530300, 530311, 530317, A61K 5100, A61M 3614
Patent
active
058304312
ABSTRACT:
This invention relates to radiolabeled peptide compositions for radiopharmaceutical use and, more specifically, to radiolabeled peptides for diagnostic or therapeutic use having an unmodified carboxy terminal amino acid. The radiopharmaceutical composition may be used for targeting a selected biological site. The radiolabeled peptide is characterized by having its carboxy terminal amino acid in its carboxylic acid form and the peptide is coupled to a diagnostic or therapeutic radionuclide by a chelating agent. The radiopharmaceutical composition preferably comprises a radiolabeled peptide selected from the group consisting of somatostatin, an analog of somatostatin, a derivative of somatostatin and peptides capable of binding to the somatostatin receptor, where the peptide is coupled to a diagnostic or therapeutic radionuclide by a chelating agent has its carboxy terminal amino acid in its carboxylic acid form.
REFERENCES:
patent: 4282143 (1981-08-01), Sarantakis
patent: 4395403 (1983-07-01), Bauer et al.
patent: 4440904 (1984-04-01), Sarantakis
patent: 4585755 (1986-04-01), Morgan et al.
patent: 4725577 (1988-02-01), Schally et al.
patent: 5225180 (1993-07-01), Dean et al.
patent: 5411943 (1995-05-01), Bogden
patent: 5650134 (1997-07-01), Albert et al.
Patel (1990), The New England Journal of Medicine, vol. 323, No. 18, pp. 1274-1276, "Somatostatin-Receptor Imaging for the Detection of Tumors".
Kvols et al (1986), The New England Journal of Medicine, vol. 315, No. 11, pp. 663-666, "Treatment of the Malignant Carcinoid Syndrome".
Ellison et al (1986), The American Journal of Medicine, vol. 81, Suppl. 6B, pp. 56-63, "Characterization of the in Vivo and in Vitro Inhibition of Gastrin Secretion from Gastrinoma by a Somatostatin Analogue (SMS 201-995)".
Bauer et al (1982), Life Sciences, vol. 31, pp. 1133-1140, "SMS 201-995: A very Potent and Selective Octapeptide Analogue of Somatostatin With Prolonged Action".
de Jong et al (1992, thesis report), pp. 89-101, Radiopharmaceuticals for Scintigraphy of Somatostatin Receptor Positive Tumors, Chapter 7: Kinetic In-DTPA-D-Phe.sup.1 !-octreotide by the isolated perfused rat liver.
Bugaj Joseph E.
Dyszlewski Mary Marmion
Erion Jack L.
Srinivasan Ananthachari
Boone Jeffrey S.
Jones Dameron
Kight John
Mallinckrodt Medical Inc.
McBride Thomas P.
LandOfFree
Radiolabeled peptide compositions for site-specific targeting does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Radiolabeled peptide compositions for site-specific targeting, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Radiolabeled peptide compositions for site-specific targeting will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-686495